Use of blood products during the first months of COVID-19 pandemic period: A single center report

Sándor Pál; Barbara Réger; Hussain Alizadeh; Árpád Szomor; András Vereczkei; Tamás Kiss; Attila Miseta; Margit Solymár; Zsuzsanna Faust

doi:10.1016/j.heliyon.2023.e14391

Use of blood products during the first months of COVID-19 pandemic period: A single center report

Heliyon. 2023 Mar;9(3):e14391. doi: 10.1016/j.heliyon.2023.e14391. Epub 2023 Mar 9.

Authors

Sándor Pál¹, Barbara Réger², Hussain Alizadeh³, Árpád Szomor³, András Vereczkei⁴, Tamás Kiss⁵, Attila Miseta², Margit Solymár¹, Zsuzsanna Faust¹

Affiliations

¹ University of Pécs, Medical School, Department of Laboratory Medicine, Department of Transfusion Medicine, Hungary.
² University of Pécs, Medical School, Department of Laboratory Medicine, Hungary.
³ University of Pécs, Medical School, 1st Department of Internal Medicine, Division of Hematology, Hungary.
⁴ University of Pécs, Medical School, Department of Surgery, Hungary.
⁵ University of Pécs, Medical School, Department of Anesthesiology and Intensive Therapy, Hungary.

Abstract

The novel coronavirus (SARS-CoV-2) outbreak exerted a serious effect on healthcare. Between 1st of January and May 31, 2020 due to the special regulations in Hungary, the number of reported COVID-19 infections were relatively low (3876 cases). The inpatient and outpatient care and the blood supply were significantly affected by the implemented regulations. The aim of this study was to evaluate the use of blood products amid the first five months of the pandemic situation. This investigation has observed a significant reduction of hospitalizations (37.35%). Analyzing individually the included units, pre-transfusion hemoglobin concentrations of transfused patients presented slight modifications, which were not statistically significant. The special regulations resulted major changes in the frequency of diagnoses at admissions in case of the Department of Surgery, while in case of the other specialities (Division of Hematology and Department of Anesthesiology and Intensive Therapy), there were no major changes compared to pre-pandemic period. Considering each department separately, transfused red blood cell concentrates (RBC) per patient, and the proportion of transfused patients did not change significantly. However, the combination of these modifications resulted in the significant decrease in RBC transfusions (p < 0.0001) compared to the pre-pandemic baseline. With regard to platelet and fresh frozen plasma (FFP), their usage was significantly reduced (44.40% platelet concentrates and 34.27% FFP). Our results indicate that the pandemic had an important effect on the blood product usage at the included departments by introducing different patient care policies and the temporary deferral of the elective surgical interventions. Despite the challenging circumstances of blood collection and blood product supply, the hospitalized patients received adequate care.

Keywords: Blood components; COVID-19 and blood product usage; Patient blood management; Pre-transfusion hemoglobin; Restrictive transfusion policy.